All In Biotech

Drug Trial Radar · NCT07421284

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia (Non-familial) or Mixed Dyslipidemia on a Background of Lipid-lowering Therapy

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Dec 31, 2027

Study completion Jan 31, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy. This trial plans to enroll 900 Participants.

Conditions

  • Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Interventions

  • SYH2053/placebo injectionDrug

    Participants receive SYH2053/placebo injection by subcutaneous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in LDL-C relative to baselineTime frame: Day 330

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliation: Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.